Inhibition of Fumarate Reductase inLeishmania major and L. donovani by Chalcones

ABSTRACT Our previous studies have shown that chalcones exhibit potent antileishmanial and antimalarial activities in vitro and in vivo. Preliminary studies showed that these compounds destroyed the ultrastructure of Leishmania parasite mitochondria and inhibited the respiration and the activity of mitochondrial dehydrogenases of Leishmania parasites. The present study was designed to further investigate the mechanism of action of chalcones, focusing on the parasite respiratory chain. The data show that licochalcone A inhibited the activity of fumarate reductase (FRD) in the permeabilized Leishmania major promastigote and in the parasite mitochondria, and it also inhibited solubilized FRD and a purified FRD from L. donovani. Two other chalcones, 2,4-dimethoxy-4′-allyloxychalcone (24m4ac) and 2,4-dimethoxy-4′-butoxychalcone (24mbc), also exhibited inhibitory effects on the activity of solubilized FRD in L. majorpromastigotes. Although licochalcone A inhibited the activities of succinate dehydrogenase (SDH), NADH dehydrogenase (NDH), and succinate- and NADH-cytochrome c reductases in the parasite mitochondria, the 50% inhibitory concentrations (IC50) of licochalcone A for these enzymes were at least 20 times higher than that for FRD. The IC50 of licochalcone A for SDH and NDH in human peripheral blood mononuclear cells were at least 70 times higher than that for FRD. These findings indicate that FRD, one of the enzymes of the parasite respiratory chain, might be the specific target for the chalcones tested. Since FRD exists in the Leishmaniaparasite and does not exist in mammalian cells, it could be an excellent target for antiprotozoal drugs.

[1]  R. Prichard.  The fumarate reductase reaction of Haemonchus contortus and the mode of action of some anthelmintics. , 1973, International journal for parasitology.

[2]  O. Lucas Adetokunho,et al.  Special Programme for Research and Training in Tropical Diseases (TDR) TDR- FINAL REPORT SERIES , 2001 .

[3]  A. Lucas.  The UNDP/world bank/WHO special programme for research and training in tropical diseases. , 1978, Papua and New Guinea medical journal.

[4]  P. Trigg.  Research and training in tropical diseases , 1979 .

[5]  J. Berman,et al.  An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. , 1980, The Journal of infectious diseases.

[6]  J. Turrens,et al.  Fumarate reductase and other mitochondrial activities in Trypanosoma cruzi. , 1986, Molecular and biochemical parasitology.

[7]  J. Turrens.  Possible role of the NADH-fumarate reductase in superoxide anion and hydrogen peroxide production in Trypanosoma brucei. , 1987, Molecular and biochemical parasitology.

[8]  L. Nolan.  Molecular target of the antileishmanial action of sinefungin , 1987, Antimicrobial Agents and Chemotherapy.

[9]  S. Itoh,et al.  ESR studies on iron‐sulfur clusters of complex II in Ascaris suum mitochondria which exhibits strong fumarate reductase activity , 1988, FEBS letters.

[10]  C. Schofield,et al.  UNDP/World Bank/WHO special programme for research and training in tropical diseases (TDR) , 1989 .

[11]  J. Turrens.  The role of succinate in the respiratory chain of Trypanosoma brucei procyclic trypomastigotes. , 1989, The Biochemical journal.

[12]  V. Ram,et al.  Chemotherapeutic agents XI: synthesis of pyrimidines and azolopyrimidines as leishmanicides☆ , 1990 .

[13]  J. Turrens,et al.  A soluble fumarate reductase in Trypanosoma brucei procyclic trypomastigotes. , 1991, The Journal of protozoology.

[14]  J. Beesley,et al.  Mitochondria of mammalian Plasmodium spp. , 1991, Parasitology.

[15]  H. Rubbo,et al.  Succinate-dependent metabolism in Trypanosoma cruzi epimastigotes. , 1992, Molecular and biochemical parasitology.

[16]  A. Bryceson,et al.  Practical progress and new drugs for changing patterns of leishmaniasis. , 1993, Parasitology today.

[17]  S. Christensen,et al.  Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania , 1993, Antimicrobial Agents and Chemotherapy.

[18]  M. Grogl,et al.  Herbicides to curb human parasitic infections: in vitro and in vivo effects of trifluralin on the trypanosomatid protozoans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Blum.  Intermediary metabolism of Leishmania. , 1993, Parasitology today.

[20]  M. Ouellette,et al.  Mechanisms of drug resistance in Leishmania. , 1993, Parasitology today.

[21]  Energy metabolism in Leishmania. , 1994, Journal of bioenergetics and biomembranes.

[22]  S. Christensen,et al.  Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani , 1994, Antimicrobial Agents and Chemotherapy.

[23]  The trypanosomatidae: Amazing organisms , 1994, Journal of bioenergetics and biomembranes.

[24]  L. Zhai,et al.  Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection , 1994, Antimicrobial Agents and Chemotherapy.

[25]  V. Massey.  FLAVOPROTEIN STRUCTURE AND MECHANISM , 1995 .

[26]  R. Krauth-Siegel,et al.  Flavoprotein structure and mechanism. 5. Trypanothione reductase and lipoamide dehydrogenase as targets for a structure-based drug design. , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  L. Zhai,et al.  The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria , 1995, Antimicrobial agents and chemotherapy.

[28]  K. Santhamma,et al.  Characterization of the respiratory chain of Leishmania donovani promastigotes. , 1995, Molecular and biochemical parasitology.

[29]  A. Osuna,et al.  Activity and mode of action of acridine compounds against Leishmania donovani , 1996, Antimicrobial agents and chemotherapy.

[30]  L. Zhai,et al.  The novel oxygenated chalcone, 2,4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. , 1997, The Journal of infectious diseases.

[31]  Martin Olivier,et al.  Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages , 1997, The EMBO journal.

[32]  V. Yardley,et al.  Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis , 1997, Antimicrobial agents and chemotherapy.

[33]  V. Yardley,et al.  Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines. , 1997, Journal of medicinal chemistry.

[34]  J. Berman.  Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  D. Rees,et al.  Structure of the Escherichia coli fumarate reductase respiratory complex. , 1999, Science.

[36]  L. Zhai,et al.  The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. , 1999, The Journal of antimicrobial chemotherapy.

[37]  G. H. Coombs,et al.  Enzymes of parasite thiol metabolism as drug targets. , 1999, Parasitology today.

[38]  M. Bogyo,et al.  Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Fox,et al.  Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. , 2000, Microbial pathogenesis.

[40]  H. Majumder,et al.  Luteolin, an Abundant Dietary Component is a Potent Anti-leishmanial Agent that Acts by Inducing Topoisomerase II-mediated Kinetoplast DNA Cleavage Leading to Apoptosis , 2000, Molecular medicine.

[41]  Separation of NADH-fumarate reductase and succinate dehydrogenase activities in Trypanosoma cruzi. , 2000, FEMS microbiology letters.

[42]  V. Yardley,et al.  Activity of the Novel Immunomodulatory Compound Tucaresol against Experimental Visceral Leishmaniasis , 2000, Antimicrobial Agents and Chemotherapy.